Adenosine therapy can help with a Coronavirus, Asthma and other respiratory a problems, know details
The introduction of adenosine therapy can be a revolutionary for chronic respiratory a diseases like a tuberculosis, lung fibrosis, asthma, and the a novel a coronavirus, India-based nutraceutical firm, Ojasveda has put a together a research inclusive study on the subject matter. For the Adenosine therapy, the study proposed an an immune-modulatory a compound named 3′-Deoxyadenosine derived from a rare species of a mushroom. Effects of this a compound later are seen in the positive a light when used along with PA-824 also marketed as a Pretomanid.
The proposed a treatment a demonstrated how a colony-forming units/Counts have a shown an immense a decline when a treated with adenosine a therapy for a period of 8 weeks.
The Adenosine Therapy improved the quality of a life of the patients by reducing asthma-related symptoms and asthma a onset frequency / severity, while it a significantly an attenuated as a thma-induced inflammation at a 3-month intervention period, as a demonstrated by decreased expression of an inflammatory a biomarkers.
Adenosine therapy is a also a reported to have pro-apoptotic effects on human lung adenocarcinoma A549 cells, to a reduce the survival of hepatocellular fibrosis and the spread cystic a formation. Research also a suggested how the effects were more an elaborate when acted as an adjuvant to the prescribed a regime.
Later this year, Ojasveda will be a releasing a much elaborate study for the an Introduction of the now researched Adenosine Therapy and regulating it with all mandated requirements with the list of clinics where the proposed therapy will be an introduced for a more profound a clinical studies.
No comments:
Post a Comment